Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Price Target at $7.50

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.50.

A number of brokerages have commented on STTK. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Leerink Partners initiated coverage on Shattuck Labs in a research note on Monday, March 17th. They set an “outperform” rating and a $4.00 target price for the company. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th.

Shattuck Labs Price Performance

Shares of STTK opened at $0.77 on Friday. The business has a 50-day moving average of $1.15 and a 200-day moving average of $1.20. The company has a market capitalization of $37.04 million, a price-to-earnings ratio of -0.51 and a beta of 1.76. Shattuck Labs has a 1 year low of $0.69 and a 1 year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, sell-side analysts anticipate that Shattuck Labs will post -1.48 EPS for the current year.

Hedge Funds Weigh In On Shattuck Labs

A number of large investors have recently modified their holdings of STTK. State Street Corp lifted its stake in shares of Shattuck Labs by 7.8% in the third quarter. State Street Corp now owns 766,410 shares of the company’s stock valued at $2,675,000 after buying an additional 55,579 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs in the 3rd quarter worth about $144,000. Barclays PLC lifted its position in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after acquiring an additional 40,717 shares in the last quarter. Geode Capital Management LLC boosted its stake in Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock worth $96,000 after purchasing an additional 10,667 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.